ストックスクリーナーアプリを入手
1.9666
7.07%
0.1266
前日終値:
$1.84
開ける：
$1.866
24時間の取引高:
24,547
Relative Volume:
0.42
時価総額：
$82.21M
収益：
$134.00K
当期純損益:
$-9.93M
株価収益率:
-5.7841
EPS:
-0.34
ネットキャッシュフロー:
$-6.72M
1週間 パフォーマンス:
+8.84%
1か月 パフォーマンス:
+1.03%
6か月 パフォーマンス:
+6.49%
1年 パフォーマンス:
-3.90%
1日の値動き範囲:
$1.82
$1.95
1週間の範囲:
$1.7501
$1.95
52週間の値動き範囲:
$1.41
$2.79
Entera Bio Ltd Stock (ENTX) Company Profile
名前
Entera Bio Ltd
セクター
電話
972-2-532-7151
住所
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
ENTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.95 | 82.21M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.28 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.12 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.96 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.62 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-22 | 開始されました | Aegis Capital | Buy |
Entera Bio Ltd (ENTX) 最新ニュース
Entera Bio reports positive phase 2 results for osteoporosis treatment By Investing.com - Investing.com South Africa
Entera Bio reports positive phase 2 results for osteoporosis treatment - Investing.com
Game-Changing Oral Osteoporosis Treatment Matches Injectable Efficacy in Clinical Trial - Stock Titan
Entera Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Entera Bio Reports Transformative Year in 2024 - TipRanks
Entera Bio Ltd. (ENTX) reports earnings - Quartz
Entera Bio Announces 2024 Financial Results and Updates - TipRanks
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech
OPKO and Entera team up on oral obesity candidate - The Pharma Letter
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement - StreetInsider
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Bio Join Forces for Game-Changing Pill - Stock Titan
Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World
Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire
Entera Bio to Participate in Upcoming Events - GlobeNewswire
Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World
Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa
Entera Bio files Exhibit 5.1 with SEC - Investing.com
Entera Bio Ltd (ENTX) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):